In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1320-1321

  Singhal, Lipika ^a   Gautam, Vikas ^a   Kaur, Mandeep ^a   Ray, Pallab ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BIOCHEMISTRY; BURKHOLDERIA CEPACIA; DISK DIFFUSION; ESCHERICHIA COLI; FIBROSIS; HUMAN; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NON CYSTIC FIBROSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA COMPLEX; CARBAPENEMS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 79952350472     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01386-10     Document Type: Letter

References (7)

1. Andes, D. R., S. Kiem, and W. A. Craig. 2003. In vivo pharmacodynamic activity of a new carbapenem, doripenem (DOR), against multiple bacteria in a murine thigh infection model, abstr. A-308, p. 10. Prog. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
2. Bhavnani, S. M., J. P. Hammel, and B. B. Cirincioni. 2003. PK-PD target attainment with Monte Carlo simulation as decision support of phase 2/3 dosing strategies for clinical development of doripenem (DOR), abstr. A-11, p. 2. Prog. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
3. CLSI. 2010. Performance standards for antimicrobial susceptibility testing. Document M100-S20. CLSI, Wayne, PA.
4. Gautam, V., et al. 2010. Burkholderia cepacia complex in septicaemic noncystic fibrosis cases from two tertiary care hospitals in north India. Indian J. Med. Res. 131:829-832.
5. LiPuma, J. J., B. J. Currie, G. D. Lum, and P. Vandamme. 2007. Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea, Brevundimonas, Comamonas, Delftia and Acidovorax, p. 749-769. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
6. Mahenthiralingam, E., et al. 2000. DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J. Clin. Microbiol. 38:3165-3173.
7. Traczewski, M. M., and S. D. Brown. 2006. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother. 50:819-821.